Polymyalgia rheumatica and giant cell arteritis are relatively common, but under research inflammatory rheumatological conditions. This survey aimed to ascertain the matters in which patients feel they need support with these conditions and appraise how the Charity PMRGCAuk currently supports these needs and could do so in the future. PMRGCAuk members (n = 910) were invited to complete an on-line survey. The survey requested the respondent's history of PMR and or GCA, their perceived priorities for support for people with PMR and or GCA and views on the services already provided by the Charity. A total of 209 people completed the survey. Less than 24% had heard of either PMR or GCA before their diagnosis. Priorities in supporting people with PMR and or GCA included: being on and tapering off glucocorticoids (76.6%), specifically, length of treatment and the risks versus benefits and managing side effects. Respondents generally reported satisfaction with the services currently provided by PMRGCAuk. The support provided by PMRGCAuk is very helpful to members and fills an important gap in provision for people with PMR and or GCA. The areas in which the greatest proportions of participants requested support do not have an evidence base to underpin them. It is incumbent on the research community to address patients' concerns and provide an evidence base where it is required by those affected.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-018-4220-1DOI Listing

Publication Analysis

Top Keywords

pmr gca
20
people pmr
12
perceived priorities
8
polymyalgia rheumatica
8
rheumatica giant
8
giant cell
8
cell arteritis
8
provided pmrgcauk
8
evidence base
8
support
5

Similar Publications

Objectives: To determine if the subtype of vascular ultrasound (US) presentation is associated with different types of ischaemic complications (IC) in giant cell arteritis (GCA).

Methods: Retrospective observational analysis of GCA clinically confirmed patients referred to US fast-track clinics at two centres. All patients underwent baseline US of cranial and extracranial arteries (carotid, subclavian and axillary).

View Article and Find Full Text PDF

Infective agents and polymyalgia rheumatica: key discussion points emerging from a narrative review of published literature.

Reumatologia

November 2024

Department of Primary Care, Health District of Soverato, Azienda Sanitaria Provinciale Catanzaro, Italy.

Introduction: The aetiology of polymyalgia rheumatica (PMR) is unknown. Recently, reports on cases of PMR following the coronavirus disease 2019 (COVID-19) have revived the role of infection as an aetiological or triggering factor. It is estimated that patients with PMR have manifestations of giant cell arteritis (GCA) in < 20% of cases.

View Article and Find Full Text PDF

Baricitinib in polymyalgia rheumatica and giant cell arteritis: report of six cases.

Reumatismo

October 2024

Division of Rheumatology, "La Colletta" Hospital, Azienda Sociosanitaria Ligure 3, Arenzano.

Article Synopsis
  • This case series evaluates the effectiveness and safety of baricitinib (BARI) in treating six patients suffering from polymyalgia rheumatica (PMR) and giant cell arteritis (GCA), particularly when traditional treatments like tocilizumab were unavailable.
  • Patients showed significant improvement in symptoms, with a notable reduction in their disease activity scores and the ability of some to discontinue glucocorticoids while on BARI.
  • Overall, the findings align with previous studies indicating that Janus kinase inhibitors may serve as a helpful alternative for managing PMR and GCA by reducing reliance on glucocorticoids, although one patient did experience pneumonia after treatment.
View Article and Find Full Text PDF

Purpose Of Review: There have been advances in the diagnosis and treatment of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR).

Recent Findings: Themes in PMR and GCA include classification criteria, ultrasound imaging of temporal and axillary arteries replacing biopsies for diagnosis of GCA, faster diagnosis and treatment with rapid access clinics for suspected GCA, and expanding treatment options with the goal of rapid suppression of inflammation and sparing steroids.

Summary: Treatment is aimed at suppressing inflammation quickly in both GCA and PMR.

View Article and Find Full Text PDF

Although its role has been debated, temporal artery biopsy (TAB) remains the gold standard for the diagnosis of cranial giant cell arteritis (GCA). The specificity of TAB is excellent and the sensitivity, albeit lower, is comparable with other diagnostic modalities used for the diagnosis of GCA. This outpatient procedure has a low rate of complications and is well integrated in the majority of healthcare systems.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!